Andrew Sinclair
Partner & Portfolio Manager @ Abingworth
London, United Kingdom
Andrew Sinclair is a Series A investor at Abingworth in London focused on Biotechnology and Medical. Andrew has more than 10 years experience as an analyst in the pharmaceutical and biotechnology sectors. He joined Abingworth in 2008 from HSBC Global Markets, where he was Senior Equity Analyst, Director, responsible for investment research in the mid-cap pharmaceutical sector. Previously, Andrew held biotechnology analyst positions at CreditSuisse and SG Cowen. He completed a PhD in Chemistry and Genetic Engineering at the BBSRC Institute of Plant Science, Norwich, and holds a BSc in Microbiology from King’s College London. Andrew qualified as a chartered accountant with KPMG. At Abingworth, he evaluates opportunities in public companies and is a fund manager for open market transactions.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 75%
Last updated:
For AI agents: llms.txt
Industries Andrew Sinclair invests in
Stages Andrew Sinclair invests in
Countries Andrew Sinclair invests in
Investment Focus
Industry
- Biotechnology 4 (100%)
- Medical 3 (75%)
- Therapeutics 2 (50%)
- Biopharma 1 (25%)
- Consulting 1 (25%)
Stage
- Series A 3 (75%)
- Post-IPO Equity 1 (25%)
Country
- United States 2 (50%)
- United Kingdom 2 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
R1 Therapeutics
|
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug therapies for patients with kidney disease. The company’s primary work centers on advancing AP306, a therapeutic candidate designed to treat hyperphosphatemia—a condition of elevated phosphate levels that commonly affects individuals withchronic kidney disease on dialysis—by blocking key active phosphate transport pathways in the gut. In its operations, R1 Therapeutics works on progressing AP306 through mid- and late-stage clinical studies and aims to bring an alternative treatment option to patients struggling with phosphate management complications associated with chronic kidney disease. | $77.5M / Series A / Mar 17, 2026 | |
Ascend Gene & Cell Therapies
|
Ascend Gene & Cell Therapies supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form. | $65.9M / Series A / Mar 20, 2023 | |
Entact Bio
|
Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function. It was founded by a team with deep roots in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development. The company's proprietary EncompassTM platform was designed tocreate enhancement-targeting chimeric (ENTACTM) medicines. ENTACs take advantage of DUBs' ability to regulate proteins. | $81M / Series A / Dec 06, 2022 | |
Soleno Therapeutics
|
Soleno Therapeutics is a clinical-stage biopharmaceutical company. | $16.5M / Post-IPO Equity / Dec 19, 2018 |
Co-Investors
4BIO Capital
3 deals together
DCVC Bio
2 deals together
Walter and Eliza Hall Institute of Medical Research
2 deals together
Ajinomoto
1 deal together
Arkin Bio Ventures
1 deal together
Brandon Capital
1 deal together
About Abingworth
Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1 billion under management, Abingworth invests at all stages of development, from start-ups to publicly traded companies, and across all life sciencessectors.Supporting its portfolio companies with a team of 27 at offices in London, Menlo Park, and Boston, Abingworth has invested in 142 life science companies, completed 60 IPOs and 40 mergers and acquisitions.
Abingworth Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Brian Gallagher
Partner
|
|||
John Shields
Advisor, Science and Technology
|
|||
Quentin Lloyd-Harris
Partner
|
|||
Alex Asquith
General Counsel and Chief Financial Officer
|
|||
|
Andrew Sinclair
Partner & Portfolio Manager
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Andrew Sinclair invest in?
Andrew Sinclair invests primarily in Biotechnology, Medical and Therapeutics startups, most often at Series A and Post-IPO Equity stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Andrew Sinclair last invest?
The most recent investment recorded for Andrew Sinclair closed in Mar 2026. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
